Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 10 | 2024 | 1273 | 2.390 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2023 | 332 | 1.650 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2023 | 69 | 0.970 |
Why?
|
| Veterans | 2 | 2023 | 87 | 0.960 |
Why?
|
| Stroke Volume | 7 | 2023 | 482 | 0.850 |
Why?
|
| Coronary Occlusion | 1 | 2023 | 7 | 0.840 |
Why?
|
| Cardiovascular Agents | 1 | 2023 | 55 | 0.810 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 270 | 0.500 |
Why?
|
| Hospitalization | 4 | 2023 | 903 | 0.390 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2024 | 39 | 0.220 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 106 | 0.220 |
Why?
|
| Outpatients | 1 | 2023 | 103 | 0.210 |
Why?
|
| Humans | 14 | 2024 | 91073 | 0.200 |
Why?
|
| Guideline Adherence | 1 | 2024 | 234 | 0.200 |
Why?
|
| Comorbidity | 2 | 2023 | 963 | 0.200 |
Why?
|
| Coronary Angiography | 1 | 2023 | 246 | 0.190 |
Why?
|
| Patient Discharge | 1 | 2024 | 328 | 0.180 |
Why?
|
| Norway | 1 | 2020 | 10 | 0.180 |
Why?
|
| Muscular Diseases | 1 | 2021 | 64 | 0.180 |
Why?
|
| Protein Interaction Maps | 1 | 2020 | 51 | 0.180 |
Why?
|
| Income | 1 | 2020 | 86 | 0.170 |
Why?
|
| Inpatients | 1 | 2023 | 320 | 0.170 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 155 | 0.170 |
Why?
|
| Proteome | 1 | 2021 | 142 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2023 | 8436 | 0.170 |
Why?
|
| Hemodynamics | 1 | 2023 | 739 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2023 | 960 | 0.160 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 108 | 0.160 |
Why?
|
| Ventricular Function, Right | 1 | 2020 | 150 | 0.150 |
Why?
|
| Proteomics | 1 | 2020 | 242 | 0.150 |
Why?
|
| Ventricular Function, Left | 2 | 2020 | 618 | 0.150 |
Why?
|
| Registries | 1 | 2023 | 826 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2019 | 308 | 0.140 |
Why?
|
| Ehrlichiosis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Echocardiography | 2 | 2020 | 950 | 0.140 |
Why?
|
| Myocardium | 1 | 2020 | 579 | 0.130 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2016 | 21 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 854 | 0.130 |
Why?
|
| Obesity | 1 | 2023 | 989 | 0.130 |
Why?
|
| Multiple Organ Failure | 1 | 2016 | 55 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 691 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 371 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1093 | 0.120 |
Why?
|
| Female | 8 | 2024 | 47186 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2020 | 792 | 0.120 |
Why?
|
| Risk Factors | 1 | 2023 | 5608 | 0.100 |
Why?
|
| Ultrasonics | 1 | 2012 | 39 | 0.100 |
Why?
|
| Fluorocarbons | 1 | 2012 | 71 | 0.090 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2012 | 127 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2012 | 294 | 0.090 |
Why?
|
| Middle Aged | 5 | 2024 | 26555 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2021 | 2904 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2021 | 4367 | 0.070 |
Why?
|
| Male | 5 | 2024 | 43249 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 6847 | 0.070 |
Why?
|
| Aged | 5 | 2024 | 19574 | 0.070 |
Why?
|
| Hospitals, Veterans | 1 | 2024 | 22 | 0.060 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2024 | 18 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2024 | 93 | 0.060 |
Why?
|
| Focus Groups | 1 | 2023 | 182 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2024 | 440 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 70 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 681 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 433 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 165 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 239 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2020 | 317 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2019 | 498 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1063 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2016 | 130 | 0.030 |
Why?
|
| Adult | 3 | 2020 | 27147 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1750 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2016 | 446 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 998 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3716 | 0.030 |
Why?
|
| Microbubbles | 1 | 2012 | 40 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2012 | 173 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 308 | 0.020 |
Why?
|
| United States | 1 | 2024 | 7188 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 181 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 984 | 0.020 |
Why?
|
| Child | 1 | 2020 | 7273 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 6502 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 9411 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 1085 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2615 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 1695 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 11993 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 27783 | 0.010 |
Why?
|